RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia

American Journal of Surgical Pathology

Volumn 33, Issue 9, 2009, Pages 1348-1354

  Bahrami, Armita ^a   Weiss, Sharon W ^b   Montgomery, Elizabeth ^c   Horvai, Andrew E ^d   Jin, Long ^a   Inwards, Carrie Y ^a   Folpe, Andrew L ^a  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FGF23; Reverse transcription polymerase chain reaction, phosphaturic mesenchymal tumor; Tumor induced osteomalacia

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FORMALDEHYDE; FRIZZLED PROTEIN; PARAFFIN; PHOSPHOGLYCERATE KINASE; RNA;

ADULT; AGED; ANEURYSMAL BONE CYST; ARTICLE; CANCER DIAGNOSIS; CARCINOMA; CHONDROBLASTOMA; CHONDROMYXOID FIBROMA; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; FIBROMA; GENE EXPRESSION; HEMANGIOPERICYTOMA; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; MALE; MESENCHYMOMA; ONCOGENIC OSTEOMALACIA; PHOSPHATURIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SARCOMA; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BONE NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HUMANS; MALE; MESENCHYMOMA; MIDDLE AGED; OSTEOMALACIA; PHOSPHATES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349113905     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181aa2311     Document Type: Article

References (27)

1. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26: 345-348.
2. Baker AC, Rezeanu L, O?Laughlin S, et al. Juxtacortical chon-dromyxoid fibroma of bone: a unique variant: a case study of 20 patients. Am J Surg Pathol. 2007;31:1662-1668.
3. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol. 2007;69:341-359.
4. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. 2003;112:785-794.
5. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. 2001;284:977-981.
6. Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia [comment]. N Engl J Med. 1994;330: 1645-1649.
7. De Beur SM, Finnegan RB, Vassiliadis J, et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res. 2002;17:1102-1110.
8. Econs MJ, Drezner MK. Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med. 1994;330:1679-1681.
9. Econs MJ, McEnery PT, Lennon F, et al. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest. 1997;100:2653-2657.
10. Evans DJ, Azzopardi JG. Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet. 1972;1:353-354.
11. Favus MJ, American Society for Bone and Mineral Research. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006.
12. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomala-cia- associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1-30.
13. Kasper DL, Harrison TR. Harrison?s principles of internal medicine. 16th ed. New York: McGraw-Hill, Medical Pub. Division; 2005.
14. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens. 2002;11:547-553.
15. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087-3094.
16. Miyauchi A, Fukase M, Tsutsumi M, et al. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxy-vitamin D 1-hydroxylase activity. J Clin Endocrinol Metab. 1988; 67:46-53.
17. Olefsky J, Kempson R, Jones H, et al. "Tertiary" hyperparathyr-oidism and apparent "cure" of vitamin-D-resistant rickets after removal of an ossifying mesenchymal tumor of the pharynx. N Engl J Med. 1972;286:740-745.
18. Oliveira AM, Perez-Atayde AR, Inwards CY, et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneur-ysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol. 2004;165:1773-1780.
19. Prader A, Illig R, Uehlinger RE, et al. Rachitis infolge knochentu-mors (Rickets caused by bone tumors). Helv Pediatr Acta. 1959; 14:554-565.
20. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004;65:1-14.
21. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500-6505.
22. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409-414.
23. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59:1442-1454.
24. Weidner N, Bar RS, Weiss D, et al. Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer. 1985;55:1691-1705.
25. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86:497-500.
26. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494-498.
27. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87:4957-4960.